Immunocore (NASDAQ:IMCR) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Immunocore (NASDAQ:IMCR) in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $100.00 price objective on the stock. HC Wainwright also issued estimates for Immunocore’s FY2027 earnings at $1.10 EPS, FY2028 earnings at $4.46 EPS and FY2029 earnings at $7.96 EPS.

A number of other equities analysts have also commented on the company. Morgan Stanley reaffirmed an “equal weight” rating and issued a $35.00 price target (down from $74.00) on shares of Immunocore in a report on Friday, December 13th. Mizuho lowered Immunocore from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $72.00 to $38.00 in a report on Monday, November 11th. Finally, Needham & Company LLC reissued a “buy” rating and set a $71.00 price objective on shares of Immunocore in a research note on Thursday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat, Immunocore presently has a consensus rating of “Moderate Buy” and an average target price of $65.64.

Immunocore Stock Performance

NASDAQ:IMCR opened at $29.37 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The business has a fifty day simple moving average of $30.08 and a two-hundred day simple moving average of $31.89. Immunocore has a 1 year low of $27.69 and a 1 year high of $72.05. The company has a market capitalization of $1.47 billion, a P/E ratio of -30.92 and a beta of 0.77.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new position in Immunocore during the 4th quarter valued at about $25,000. China Universal Asset Management Co. Ltd. raised its position in shares of Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after acquiring an additional 960 shares in the last quarter. NEOS Investment Management LLC raised its position in shares of Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock worth $330,000 after acquiring an additional 1,102 shares in the last quarter. Tema Etfs LLC bought a new position in shares of Immunocore in the 4th quarter worth approximately $330,000. Finally, Virtus ETF Advisers LLC raised its position in shares of Immunocore by 39.0% in the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock worth $340,000 after acquiring an additional 3,238 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.